150 related articles for article (PubMed ID: 23330563)
1. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management.
Geist BJ; Egan AC; Yang TY; Dong Y; Shankar G
Bioanalysis; 2013 Jan; 5(2):227-44. PubMed ID: 23330563
[TBL] [Abstract][Full Text] [Related]
2. Critical ligand binding reagent preparation/selection: when specificity depends on reagents.
Rup B; O'Hara D
AAPS J; 2007 May; 9(2):E148-55. PubMed ID: 17614357
[TBL] [Abstract][Full Text] [Related]
3. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents.
Staack RF; Stracke JO; Stubenrauch K; Vogel R; Schleypen J; Papadimitriou A
Bioanalysis; 2011 Mar; 3(5):523-34. PubMed ID: 21388265
[TBL] [Abstract][Full Text] [Related]
4. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.
O'Hara DM; Theobald V; Egan AC; Usansky J; Krishna M; TerWee J; Maia M; Spriggs FP; Kenney J; Safavi A; Keefe J
AAPS J; 2012 Jun; 14(2):316-28. PubMed ID: 22415613
[TBL] [Abstract][Full Text] [Related]
5. Sponsor relationships, analyte stability in ligand-binding assays and critical reagent management: a bioanalytical CRO perspective.
Lefor Bradford J
Bioanalysis; 2015; 7(11):1337-46. PubMed ID: 26110706
[TBL] [Abstract][Full Text] [Related]
6. Life cycle management of critical ligand-binding reagents.
O'Hara DM; Theobald V
Bioanalysis; 2013 Nov; 5(21):2679-96. PubMed ID: 24180507
[TBL] [Abstract][Full Text] [Related]
7. Adventures in critical reagent lot changes in ligand-binding assays: redevelopment, bridging and additional processing requirements.
Rauwerdink A; Benson M; Jayne A; Babu S; St Charles J; Smith A
Bioanalysis; 2021 May; 13(10):771-777. PubMed ID: 33884890
[No Abstract] [Full Text] [Related]
8. Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC-MS.
Santockyte R; Zeng J; Zheng N
Bioanalysis; 2019 Apr; 11(8):785-795. PubMed ID: 30994008
[TBL] [Abstract][Full Text] [Related]
9. Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance.
Haulenbeek J; Piccoli SP
Bioanalysis; 2014 Apr; 6(7):983-92. PubMed ID: 24806906
[TBL] [Abstract][Full Text] [Related]
10. Critical reagent generation, characterization, handling and storage workflows: impact on ligand binding assays.
Oquendo E; Savoie J; Swenson JM; Grimaldi C
Bioanalysis; 2021 May; 13(10):847-860. PubMed ID: 33890503
[TBL] [Abstract][Full Text] [Related]
11. Current industrial practices and regulatory requirements to assess analyte and reagent stability using ligand-binding assays.
Wang J; Nowatzke W; Ma M
Bioanalysis; 2015; 7(11):1371-84. PubMed ID: 26110710
[TBL] [Abstract][Full Text] [Related]
12. Bioanalytical considerations in the comparability assessment of biotherapeutics.
Lee JW; Wang YM; Moxness M; DeSilva B
Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
[TBL] [Abstract][Full Text] [Related]
13. Critical reagent characterization and re-evaluation to ensure long-term stability: two case studies.
Caiazzo TM; Shea CM; Joyce AP
Bioanalysis; 2021 May; 13(10):807-815. PubMed ID: 33884894
[TBL] [Abstract][Full Text] [Related]
14. Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift.
Azadeh M; Sondag P; Wang Y; Raines M; Sailstad J
AAPS J; 2019 Jul; 21(5):89. PubMed ID: 31297703
[TBL] [Abstract][Full Text] [Related]
15. The importance of quality critical reagents for the entire developmental lifecycle of a biopharmaceutical: a pharmacokinetic case study.
Mayer AP; Fraley KJ
Bioanalysis; 2021 May; 13(10):817-827. PubMed ID: 33769084
[No Abstract] [Full Text] [Related]
16. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins.
Ray CA; Patel V; Shih J; Macaraeg C; Wu Y; Thway T; Ma M; Lee JW; Desilva B
J Pharm Biomed Anal; 2009 Feb; 49(2):311-8. PubMed ID: 19150188
[TBL] [Abstract][Full Text] [Related]
17. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
[TBL] [Abstract][Full Text] [Related]
18. Laboratory automation of high-quality and efficient ligand-binding assays for biotherapeutic drug development.
Wang J; Patel V; Burns D; Laycock J; Pandya K; Tsoi J; DeSilva B; Ma M; Lee J
Bioanalysis; 2013 Jul; 5(13):1635-48. PubMed ID: 23822127
[TBL] [Abstract][Full Text] [Related]
19. EBF recommendation on practical management of critical reagents for PK ligand-binding assays.
Pihl S; van der Strate BW; Golob M; Vermet L; Jaitner B; Goodman J; Fjording MS; Timmerman P
Bioanalysis; 2018 Oct; 10(19):1557-1565. PubMed ID: 30226086
[TBL] [Abstract][Full Text] [Related]
20. Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics.
Duo J; Bruno J; Kozhich A; David-Brown D; Luo L; Kwok S; Santockyte R; Haulenbeek J; Liu R; Hamuro L; Peterson JE; Piccoli S; DeSilva B; Pillutla R; Zhang YJ
Bioanalysis; 2018 Apr; 10(8):559-576. PubMed ID: 29701071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
